Project Grant R01CA298153
Award Date
12/13/24
Completion Date
11/30/29
Dollars Obligated
$691K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This $162,486 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by New York University School of Medicine to characterize how T-cell acute lymphoblastic leukemia (T-ALL) infiltrates the central nervous system (CNS). The research aims to determine if T-ALL cells traffic through bridging channels in the skull bone marrow to seed the meninges, and whether integrins are required for T-ALL entry into the CNS. Using novel...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $662,938 to Northwestern University to conduct research aimed at understanding the role of gain-of-function mutant p53 proteins in promoting leukemia-initiating cell (LIC) self-renewal, chromatin accessibility, and 3D chromatin structure. The research will employ molecular, biochemical, genetic, and pharmacological approaches, as well as genome-wide analyses including RNA-seq,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $234,919 to Yale University from September 1, 2024 to August 31, 2027 to develop a novel approach for multiplexed and high-sensitivity detection of gene expression using CRISPR-mediated transcriptional activation. The project aims to fluorescently report the transcriptional activity of 9 or more cytokines simultaneously, dynamically, and in situ in tissues. This will address...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Southern Illinois University School of Medicine (SIU SOM) to investigate the role of Th2 cytokines in the formation of tumor lymphatic vessels. Specifically, the $445,500 award from July 1, 2024 to June 30, 2027 will: Determine the significance of Th2 pathways in the ability of myeloid-derived lymphatic endothelial cell progenitors (M-LECP) to drive tumor lymphangiogenesis...
This $2,561,215 Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program supports a research project at Weill Medical College of Cornell University focused on understanding the epigenetic and immune mechanisms underlying diffuse large B-cell lymphoma (DLBCL). The research team will investigate how chromatin modifications and immune synapse signaling pathways shape the lymphoma microenvironment and influence DLBCL progression across a continuum of...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program provides funding of $344,111 to Loyola University of Chicago's Health Sciences Campus to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The research aims to investigate whether inhibition of the key regulator RIPK1 can prevent MDS development and restore blood cell counts, as well as whether inhibition of TBK1 can eliminate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai is for the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that jointly captures gene expression, chromatin accessibility, and DNA methylation. The goal is to apply this new technique to identify and target methylation-driven pathways in acute myeloid leukemia (AML). The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and inflammatory signaling in the leptomeningeal space. The $730,398 award, effective from March 11, 2025 to February 28, 2030, will leverage immune-competent mouse models and clinical samples to mechanistically dissect the CXCL1-CXCR2 signaling...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This $391,531 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Yale University supports the development of technology enabling directed phosphorylation of a single protein kinase substrate. The research aims to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using the tumor suppressor kinase LKB1 and its substrate AMPK as a model system. The goal is to establish a system where a single kinase...